title: Impact of high-dose chemotherapy on peripheral T-cell lymphomas.
abstract: OBJECTIVE
  To evaluate the outcome of high-dose chemotherapy (HDCT) and autologous or allogeneic hematopoietic transplantation in patients with peripheral T-cell lymphoma (PTCL) who experienced disease recurrence after prior conventional chemotherapy.
  
  
  METHODS
  We performed a retrospective analysis of 36 PTCL patients from the University of Texas M.D. Anderson Cancer Center treated between 1989 and 1998 with HDCT and autologous or allogeneic hematopoietic transplantation.
  
  
  RESULTS
  A total of 36 patients were studied (29 received autologous transplantation, and seven received allogeneic transplantation). The overall survival rate at 3 years was 36% (95% confidence interval [CI], 23% to 59%), and the progression-free survival (PFS) rate was 28% (95% CI, 16% to 49%). The pretransplant serum lactate dehydrogenase level was the most important prognostic factor for both survival and PFS rates (P < .001). A Pretransplant International Prognostic Index score of < or = 1 indicated a superior survival rate (P = .036) but not an improved PFS rate. A median follow-up of 43 months (range, 13 to 126 months) showed 13 patients (36%) were still alive with no evidence of disease.
  
  
  CONCLUSIONS
  Our results are comparable to the published data on HDCT in B-cell non-Hodgkin's lymphoma (NHL) patients despite the fact that patients with PTCL are known to have a worse outcome compared with B-cell NHL patients. Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation.
authors.affiliation: Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: J
authors.initials: J
authors.lastname: Rodriguez
authors.forename: M
authors.initials: M
authors.lastname: Munsell
authors.forename: S
authors.initials: S
authors.lastname: Yazji
authors.forename: F B
authors.initials: FB
authors.lastname: Hagemeister
authors.forename: A
authors.initials: A
authors.lastname: Younes
authors.forename: B
authors.initials: B
authors.lastname: Andersson
authors.forename: S
authors.initials: S
authors.lastname: Giralt
authors.forename: J
authors.initials: J
authors.lastname: Gajewski
authors.forename: M
authors.initials: M
authors.lastname: de Lima
authors.forename: D
authors.initials: D
authors.lastname: Couriel
authors.forename: J
authors.initials: J
authors.lastname: Romaguera
authors.forename: F F
authors.initials: FF
authors.lastname: Cabanillas
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
authors.forename: I F
authors.initials: IF
authors.lastname: Khouri
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D015996:Survival Rate; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D007770:L-Lactate Dehydrogenase